Floatz logo

Allogeneic Bone Marrow-Derived Mscs

Recurrent Plasma Cell Myeloma

Jonsson Comprehensive Cancer CenterCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Recurrent Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Cediranib
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Leflunomide
City of Hope Medical Center
Phase 2BB
Dinaciclib
National Cancer Institute (NCI)
Phase 2B
Metformin
Mayo Clinic
Phase 2B
Pelareorep
University of Southern California
Phase 1/2B

View all 41 →

Same molecule, other indications

Allogeneic Bone Marrow-Derived Mscs is also rated in:

lumbar disk degenerative disorderDormant
CCC
Indicative ·
54 / 100
View asset →
bone marrow failure syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
bipolar depressionDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →